IMAB News and Press, I-MAB From 03/31/23

2023-03-31 06:43:48 ET I-Mab Biopharma press release ( NASDAQ: IMAB ): FY Non-GAAP EPADS of -$3.58 misses by $2.75 . Revenue of $32.1M (vs.$13.8M Y/Y) misses by $69.23M . A strong cash position of  $514.2M by the end of 2022, sufficient to fund key bu...

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 PR Newswire Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resu...

2023-03-30 12:47:04 ET I-Mab Biopharma ( NASDAQ: IMAB ) is scheduled to announce FY earnings results on Thursday, March 30th, before market open. The consensus EPS Estimate is -$0.83 (+46.1% Y/Y) and the consensus Revenue Estimate is $37.13M (+169.1% Y/Y). Over the las...

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023 PR Newswire GAITHERSBURG, Md. and SHANGHAI, China , March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical co...

MSCI ESG Updated I-Mab to "A" Rating PR Newswire GAITHERSBURG, MD . and SHANGHAI , March 7, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of...

I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022 PR Newswire GAITHERSBURG, MD . and SHANGHAI , Nov. 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed t...

I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022 PR Newswire GAITHERSBURG, MD . and SHANGHAI, China , Oct. 5, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stag...

Summary Clearance from China was received to initiate a phase 3 registrational study using Lemzoparlimab for high-risk MDS patients; trial initiation is expected in Q4 of 2022. Results from phase 2 studies using uliledlimab for the treatment of patients with non-small cell lung ca...

Summary Celregen Therapeutics signed a $100 million agreement to in-license China rights for a novel therapy that uses induced Pluripotent Stem Cells to repair bullous keratopathy. Asymchem’s $58 million acquisition of Boston’s Snapdragon Chemistry, a cross-border ti...

Chinese biotech I-Mab ( NASDAQ: IMAB ) on Tuesday said it got local regulatory approval to start a phase 3 trial evaluating its antibody lemzoparlimab in combination with cancer drug azacitidine for the treatment of myelodysplastic syndrome (MDS). MDS is a group of cancers...